← Back to Search

Monoclonal Antibodies

GDC-1971 + Osimertinib/Cetuximab for Non-Small Cell Lung Cancer

Phase 1
Recruiting
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed metastatic adenocarcinoma of the colon or rectum that has progressed on/after prior treatment with an EGFR inhibitor (e.g., cetuximab or panitumumab)
Negative for acquired on-target EGFR alterations
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 41 months
Awards & highlights

Study Summary

This trial studies the safety of a drug (GDC-1971) when used with other treatments for cancer. It tests different doses and looks at effects.

Who is the study for?
This trial is for adults with certain types of advanced lung or colorectal cancer. Participants must have specific genetic mutations, good organ function, and a performance status indicating they can care for themselves. They should not have had recent major surgeries or treatments, no active infections like hepatitis or HIV, and no history of significant heart, liver, or eye disease.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of GDC-1971 when combined with Osimertinib for lung cancer patients or Cetuximab for colorectal cancer patients. It includes an initial phase to find the right dose followed by a phase to see how well it works at that dose.See study design
What are the potential side effects?
Potential side effects may include typical reactions from targeted cancer therapies such as skin rash, diarrhea, abnormal liver blood tests, fatigue and allergic reactions. The exact side effects will be monitored closely given this is a safety-focused study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My colon or rectum cancer has worsened after treatment with an EGFR inhibitor.
Select...
My cancer does not have EGFR mutations.
Select...
I am fully active or can carry out light work.
Select...
My cancer does not have KRAS gene changes.
Select...
My cancer does not have the BRAF V600E mutation.
Select...
My cancer has a specific EGFR mutation.
Select...
My cancer does not have NRAS gene changes.
Select...
My lung cancer has worsened after treatment with a specific lung cancer medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 41 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 41 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with Dose-Limiting Toxicities (DLTs)
Percentage of Participants with Adverse Events (AEs) Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Secondary outcome measures
Duration of Response (DOR) as Determined by Investigator According to RECIST v1.1
Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
Plasma Concentration of GDC-1971
+2 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Dose-Finding Stage: Non-Small Cell Lung Cancer (NSCLC)Experimental Treatment2 Interventions
Participants with unresectable, locally advanced or metastatic NSCLC will receive GDC-1971 at an assigned dose, orally, once daily (QD), on Days 1 to 28 of each 28-day cycle in combination with osimertinib, 80 milligrams (mg), orally, QD, on Days 1 to 28 of each cycle until disease progression or unacceptable toxicity.
Group II: Dose-Finding Stage: Colorectal Cancer (CRC)Experimental Treatment2 Interventions
Participants with metastatic CRC will receive GDC-1971, at an assigned dose, orally, QD, on Days 1 to 28 days of each 28-day cycle in combination with cetuximab, 500 milligrams per square meter (mg/m^2), given by IV infusion on Days 1 and 15 of each cycle, until disease progression or unacceptable toxicity.
Group III: Dose Expansion Stage: NSCLCExperimental Treatment2 Interventions
Participants with unresectable, locally advanced or metastatic NSCLC will receive GDC-1971 at a dose determined in the dose finding stage, orally, QD, on Days 1 to 28 of each 28-day cycle in combination with osimertinib, 80 mg, orally, QD, on Days 1 to 28 of each cycle until disease progression or unacceptable toxicity.
Group IV: Dose Expansion Stage: CRCExperimental Treatment2 Interventions
Participants with metastatic CRC will receive GDC-1971 at a dose determined in the dose finding stage, orally, QD, on Days 1 to 28 of each 28-day cycle in combination with cetuximab, 500 mg/m^2, given by IV infusion on Days 1 and 15 of each cycle until disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cetuximab
2011
Completed Phase 3
~2480
Osimertinib
2017
Completed Phase 4
~1010

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,541 Previous Clinical Trials
567,859 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,202 Previous Clinical Trials
889,864 Total Patients Enrolled

Media Library

Colorectal Cancer Research Study Groups: Dose-Finding Stage: Non-Small Cell Lung Cancer (NSCLC), Dose-Finding Stage: Colorectal Cancer (CRC), Dose Expansion Stage: NSCLC, Dose Expansion Stage: CRC
Colorectal Cancer Clinical Trial 2023: Cetuximab Highlights & Side Effects. Trial Name: NCT05954871 — Phase 1
~115 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top